1Department of Neurosurgery, The Loyal and Edith Davis Neurosurgical Research Laboratory, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
2Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland.
J Neurosurg. 2023 Aug 4;140(2):357-366. doi: 10.3171/2023.5.JNS23546. Print 2024 Feb 1.
Confocal laser endomicroscopy (CLE) is a US Food and Drug Administration-cleared intraoperative real-time fluorescence-based cellular resolution imaging technology that has been shown to image brain tumor histoarchitecture rapidly in vivo during neuro-oncological surgical procedures. An important goal for successful intraoperative implementation is in vivo use at the margins of infiltrating gliomas. However, CLE use at glioma margins has not been well studied.
Matching in vivo CLE images and tissue biopsies acquired at glioma margin regions of interest (ROIs) were collected from 2 institutions. All images were reviewed by 4 neuropathologists experienced in CLE. A scoring system based on the pathological features was implemented to score CLE and H&E images from each ROI on a scale from 0 to 5. Based on the H&E scores, all ROIs were divided into a low tumor probability (LTP) group (scores 0-2) and a high tumor probability (HTP) group (scores 3-5). The concordance between CLE and H&E scores regarding tumor probability was determined. The intraclass correlation coefficient (ICC) and diagnostic performance were calculated.
Fifty-six glioma margin ROIs were included for analysis. Interrater reliability of the scoring system was excellent when used for H&E images (ICC [95% CI] 0.91 [0.86-0.94]) and moderate when used for CLE images (ICC [95% CI] 0.69 [0.40-0.83]). The ICCs (95% CIs) of the LTP group (0.68 [0.40-0.83]) and HTP group (0.68 [0.39-0.83]) did not differ significantly. The concordance between CLE and H&E scores was 61.6%. The sensitivity and specificity values of the scoring system were 79% and 37%. The positive predictive value (PPV) and negative predictive value were 65% and 53%, respectively. Concordance, sensitivity, and PPV were greater in the HTP group than in the LTP group. Specificity was higher in the newly diagnosed group than in the recurrent group.
CLE may detect tumor infiltration at glioma margins. However, it is not currently dependable, especially in scenarios where low probability of tumor infiltration is expected. The proposed scoring system has excellent intrinsic interrater reliability, but its interrater reliability is only moderate when used with CLE images. These results suggest that this technology requires further exploration as a method for consistent actionable intraoperative guidance with high dependability across the range of tumor margin scenarios. Specific-binding and/or tumor-specific fluorophores, a CLE image atlas, and a consensus guideline for image interpretation may help with the translational utility of CLE.
共聚焦激光内镜(CLE)是一种获得美国食品和药物管理局批准的术中实时荧光细胞分辨率成像技术,已被证明可在神经肿瘤学手术过程中快速对脑肿瘤组织学结构进行体内成像。成功实施术中应用的一个重要目标是在浸润性胶质瘤的边缘进行体内应用。然而,CLE 在胶质瘤边缘的应用尚未得到很好的研究。
从 2 个机构收集了在胶质瘤边缘感兴趣区域(ROI)采集的匹配的体内 CLE 图像和组织活检。由 4 位具有 CLE 经验的神经病理学家对所有图像进行了回顾。实施了一种基于病理特征的评分系统,对每个 ROI 的 CLE 和 H&E 图像进行 0 到 5 的评分。根据 H&E 评分,所有 ROI 分为低肿瘤概率(LTP)组(评分 0-2)和高肿瘤概率(HTP)组(评分 3-5)。确定了 CLE 与 H&E 评分在肿瘤概率方面的一致性。计算了组内相关系数(ICC)和诊断性能。
共纳入 56 个胶质瘤边缘 ROI 进行分析。评分系统用于 H&E 图像时,其组内信度极好(ICC[95%CI]0.91[0.86-0.94]),用于 CLE 图像时为中度(ICC[95%CI]0.69[0.40-0.83])。LTP 组(ICC[95%CI]0.68[0.40-0.83])和 HTP 组(ICC[95%CI]0.68[0.39-0.83])的 ICC 无显著差异。CLE 与 H&E 评分的一致性为 61.6%。评分系统的灵敏度和特异性分别为 79%和 37%。阳性预测值(PPV)和阴性预测值分别为 65%和 53%。在 HTP 组中,一致性、灵敏度和 PPV 均大于 LTP 组。在新发组中,特异性高于复发组。
CLE 可能检测到胶质瘤边缘的肿瘤浸润。然而,它目前还不可靠,尤其是在预计肿瘤浸润概率较低的情况下。所提出的评分系统具有出色的内在组内信度,但在使用 CLE 图像时,其组内信度仅为中等。这些结果表明,该技术需要进一步探索,以作为一种在各种肿瘤边缘情况下具有高度可靠性的一致的可操作术中指导方法。特定结合和/或肿瘤特异性荧光团、CLE 图像图谱以及图像解释的共识指南可能有助于 CLE 的转化应用。